Jack L Summers

US Patent:

7091241, Aug 15, 2006

Filed:

Jun 3, 2002

Appl. No.:

10/160152

Inventors:

Jacques Gilloteaux - Kent OH, US
Henryk S. Taper - Wilsele, BE
James M Jamison - Rootstown OH, US
Jack L. Summers - Tallmadge OH, US

Assignee:

Summa Health System - Akron OH

International Classification:

A01N 43/08

US Classification:

514474, 514681, 514684

Abstract:

A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin Kis in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.

US Patent:

20060229360, Oct 12, 2006

Filed:

Mar 30, 2006

Appl. No.:

11/394311

Inventors:

Jacques Gilloteaux - Kent OH, US
Henryk Taper - Wilsele, BE
James Jamison - Rootstown OH, US
Jack Summers - Tallmadge OH, US

International Classification:

A61K 31/375
A61K 31/12

US Classification:

514474000, 514690000

Abstract:

A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin Kis in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.

US Patent:

20070043110, Feb 22, 2007

Filed:

Aug 14, 2006

Appl. No.:

11/464295

Inventors:

Jacques Gilloteaux - Kent OH, US
Henryk Taper - Brussels, BE
James Jamison - Stow OH, US
Jack Summers - Sun City Center FL, US

Assignee:

Summa Health System - Akron OH

International Classification:

A61K 31/375
A61K 31/122

US Classification:

514474000, 514682000

Abstract:

A combination of Vitamin C and a quinone used as a supplemental treatment for an ovarian cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin Kis in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.

US Patent:

20200016096, Jan 16, 2020

Filed:

Sep 26, 2019

Appl. No.:

16/584195

Inventors:

- Fairlawn OH, US
Karen M. McGuire - Akron OH, US
James M. Jamison - Cleveland Heights OH, US
Jack L. Summers - Sun City Center FL, US

Assignee:

BioMendics, LLC - Fairlawn OH

International Classification:

A61K 31/05
A61K 31/655
A61K 31/375
A61K 31/167
A61K 31/03
A61K 8/73
A61K 8/70
A61K 9/19
A61K 9/08
A61K 9/00
A61K 8/67
A61K 8/60
A61K 8/33
A61K 8/34
A61Q 7/00
A61Q 19/08
A61K 47/40
A61K 47/36
A61K 9/06
A61K 45/06
A61K 31/7034
A61K 31/09
A61K 31/085

Abstract:

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I):

US Patent:

20190022029, Jan 24, 2019

Filed:

Aug 8, 2018

Appl. No.:

16/058437

Inventors:

- Fairlawn OH, US
Karen M. McGuire - Akron OH, US
James M. Jamison - Cleveland Heights OH, US
Jack L. Summers - Sun City Center FL, US

Assignee:

BioMendics, LLC - Fairlawn OH

International Classification:

A61K 31/05
A61K 8/67
A61K 9/00
A61K 8/60
A61K 8/33
A61K 8/34
A61Q 7/00
A61Q 19/08
A61K 47/40
A61K 47/36
A61K 9/06
A61K 45/06
A61K 31/7034
A61K 31/09
A61K 31/085
A61K 8/73
A61K 9/08
A61K 9/19
A61K 8/70
A61K 31/03
A61K 31/167
A61K 31/375
A61K 31/655

Abstract:

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I):Rto Rare independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≥1. Each Rto Ris independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.

US Patent:

20160296477, Oct 13, 2016

Filed:

Apr 7, 2016

Appl. No.:

15/093146

Inventors:

- Fairlawn OH, US
Karen M. McGuire - Akron OH, US
James M. Jamison - Cleveland Heights OH, US
Jack L. Summers - Sun City Center FL, US

Assignee:

BioMendics, LLC - Fairlawn OH

International Classification:

A61K 31/05
A61K 31/085
A61K 31/09
A61K 31/7034
A61K 45/06
A61K 9/06
A61K 47/36
A61K 47/40
A61K 47/48
A61Q 19/08
A61Q 7/00
A61Q 11/00
A61Q 19/00
A61Q 17/04
A61Q 19/06
A61K 8/34
A61K 8/33
A61K 8/60
A61K 8/04
A61K 8/73
A61K 8/67
A61K 31/047

Abstract:

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I):